- Home
- SLVM vs VCEL Comparison
SLVM vs VCEL Comparison
Compare SLVM & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLVM
- VCEL
- Stock Information
- Founded
- SLVM 1898
- VCEL 1989
- Country
- SLVM United States
- VCEL United States
- Employees
- SLVM N/A
- VCEL N/A
- Industry
- SLVM Paper
- VCEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SLVM Basic Materials
- VCEL Health Care
- Exchange
- SLVM Nasdaq
- VCEL Nasdaq
- Market Cap
- SLVM 2.4B
- VCEL 2.1B
- IPO Year
- SLVM N/A
- VCEL 1997
- Fundamental
- Price
- SLVM $43.53
- VCEL $35.37
- Analyst Decision
- SLVM Hold
- VCEL Strong Buy
- Analyst Count
- SLVM 3
- VCEL 7
- Target Price
- SLVM $75.00
- VCEL $61.29
- AVG Volume (30 Days)
- SLVM 396.4K
- VCEL 614.9K
- Earning Date
- SLVM 08-08-2025
- VCEL 07-31-2025
- Dividend Yield
- SLVM 4.04%
- VCEL N/A
- EPS Growth
- SLVM N/A
- VCEL 2045.40
- EPS
- SLVM 5.23
- VCEL 0.13
- Revenue
- SLVM $3,550,000,000.00
- VCEL $249,119,000.00
- Revenue This Year
- SLVM N/A
- VCEL $23.03
- Revenue Next Year
- SLVM $0.46
- VCEL $24.51
- P/E Ratio
- SLVM $8.53
- VCEL $284.01
- Revenue Growth
- SLVM N/A
- VCEL 16.13
- 52 Week Low
- SLVM $37.52
- VCEL $33.09
- 52 Week High
- SLVM $98.02
- VCEL $63.00
- Technical
- Relative Strength Index (RSI)
- SLVM 42.42
- VCEL 42.13
- Support Level
- SLVM $37.52
- VCEL $35.24
- Resistance Level
- SLVM $46.05
- VCEL $38.08
- Average True Range (ATR)
- SLVM 1.72
- VCEL 1.85
- MACD
- SLVM -0.02
- VCEL -0.03
- Stochastic Oscillator
- SLVM 62.71
- VCEL 27.62
About SLVM Sylvamo Corporation
Sylvamo Corp is an uncoated papers company with a broad portfolio of top-tier brands and low-cost, large-scale paper mills, it produces uncoated freesheet (UFS) for paper products such as cut size and offset paper, as well as market pulp. The company offers Copy and Printer papers, Commercial Printing papers, Converting papers and Specialty papers. It operates in three geographical segments: Europe, Latin America, and North America. Key revenue is generated from North America.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.